My guess is that the PNU Phase III trial failure's repercussions for AIMM took a day to be appreciated (My prior post). There is simply no real competition for Myloral in the market place. So, if it is approved, sales should be outstanding. This, plus the fact that AIMM had become clearly oversold and undervalued, I believe fueled yesterday's rally. I doubt that if there was a leak, that, that many people knew about it. Also, IMO: it's just too soon to have results to leak. I'm guessing another two to three weeks before leaks might give us a clue as to whether positive or negative results are forthcomming.
I agree that if Myloral is approved, that AIMM will go through the roof. It will be viewed that AIMM not only has a potentially profitable drug with liklihood of approval, but more importantly, that the entire extensive pipeline has been validated. IMO: AIMM has been undervalued, because investors are skeptical regarding oral tolerance. But, if Myloral is successful, then the issue is resolved and oral tolerance has to be viewed as an effective treatment. AIMM's pipeline is so extensive and addresses such huge markets (arthritis, diabetes), that this validation should lift exprectations for AIMM tremendously and with them, the stock value.
John de C |
